Page last updated: 2024-11-02

pantoprazole and Bowel Diseases, Inflammatory

pantoprazole has been researched along with Bowel Diseases, Inflammatory in 1 studies

Pantoprazole: 2-pyridinylmethylsulfinylbenzimidazole proton pump inhibitor that is used in the treatment of GASTROESOPHAGEAL REFLUX and PEPTIC ULCER.
pantoprazole : A member of the class of benzimidazoles that is 1H-benzimidazole substituted by a difluoromethoxy group at position 5 and a [(3,4-dimethoxypyridin-2-yl)methyl]sulfinyl group at position 2.

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's0 (0.00)24.3611
2020's1 (100.00)2.80

Authors

AuthorsStudies
Wauters, L1
Ceulemans, M1
Frings, D1
Lambaerts, M1
Accarie, A1
Toth, J1
Mols, R1
Augustijns, P1
De Hertogh, G1
Van Oudenhove, L1
Tack, J1
Vanuytsel, T1

Clinical Trials (1)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
Effect of Proton Pump Inhibitors on the Duodenal Microbiome in Healthy Volunteers and Functional Dyspepsia Patients[NCT03545243]Phase 479 participants (Actual)Interventional2018-04-23Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Other Studies

1 other study available for pantoprazole and Bowel Diseases, Inflammatory

ArticleYear
Proton Pump Inhibitors Reduce Duodenal Eosinophilia, Mast Cells, and Permeability in Patients With Functional Dyspepsia.
    Gastroenterology, 2021, Volume: 160, Issue:5

    Topics: Adult; Belgium; Bile Acids and Salts; Case-Control Studies; Duodenal Diseases; Duodenum; Dyspepsia;

2021